Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.

Journal of molecular and cellular cardiology - 1 Sept 2014

Du Chunyun, Zhang Yihong, El Harchi Aziza, Dempsey Christopher E, Hancox Jules C

Abstract excerpt

The antianginal drug ranolazine, which combines inhibitory actions on rapid and sustained sodium currents with inhibition of the hERG/IKr potassium channel, shows promise as an antiarrhythmic agent. This study investigated the structural basis of hERG block by ranolazine, with lidocaine used as a low potency, structurally similar comparator. Recordings of hERG current (IhERG) were made from cell lines expressing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Action Potentials
Share to Anti-Arrhythmia Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ERG1 Potassium Channel

Share to Ether-A-Go-Go Potassium Channels

Share to Ion Transport

Share to Molecular Docking Simulation

Share to Piperazines

Share to Potassium

Source

Open in PubMed Open full text

Identifiers

PMID: 24877995
DOI: 10.1016/j.yjmcc.2014.05.013
PMCID: PMC4121676

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.PMID 24877995Read ↗

The efficacy of Ranolazine on E1784K is altered by temperature and calcium.Semantic proximity Read ↗

Structural modeling of the hERG potassium channel and associated drug interactionsSemantic proximity Read ↗

Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide.Semantic proximity Read ↗

hERG potassium channels and cardiac arrhythmia.Semantic proximity Read ↗

Molecular Basis for state-dependent drug block of Kv11.1 (HERG) potassium channelsSemantic proximity Read ↗

Molecular determinants of hERG potassium channel inhibition by disopyramide.Semantic proximity Read ↗

Structural determinants for high-affinity block of hERG potassium channels.Semantic proximity Read ↗

Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.Semantic proximity Read ↗

Investigating the state dependence of drug binding in hERG channels using a trapped-open channel phenotype.Semantic proximity Read ↗

The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.Semantic proximity Read ↗

Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.Semantic proximity Read ↗

Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.